Continuous Activity Monitoring During Concurrent Chemoradiotherapy.

[1]  S. Kalnicki,et al.  Radiation Therapy Noncompliance and Clinical Outcomes in an Urban Academic Cancer Center. , 2016, International journal of radiation oncology, biology, physics.

[2]  J. Bergman,et al.  Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma , 2014, BMC Cancer.

[3]  Jacqueline Esthappan,et al.  RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. , 2013, International journal of radiation oncology, biology, physics.

[4]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Fountzilas,et al.  A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer , 2010, Cancer Chemotherapy and Pharmacology.

[6]  J. Menzin,et al.  Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. , 2009, Archives of otolaryngology--head & neck surgery.

[7]  Cynthia S. Johnson,et al.  Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Oster,et al.  Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma , 2006, Cancer.

[9]  B E Ainsworth,et al.  How many days of pedometer monitoring predict weekly physical activity in adults? , 2005, Preventive medicine.

[10]  Y Ohno,et al.  Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer , 2001, British Journal of Cancer.

[11]  S. Kudoh,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Ian N. Olver,et al.  Observer error in grading performance status in cancer patients , 1999, Supportive Care in Cancer.

[13]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[14]  C. Earle,et al.  Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  M. Lindstrom,et al.  Loss of local control with prolongation in radiotherapy. , 1992, International journal of radiation oncology, biology, physics.

[16]  T. Hutchinson,et al.  Scientific problems in clinical scales, as demonstrated in the Karnofsky index of performance status. , 1979, Journal of chronic diseases.